DK3260457T3 - Fremgangsmåde til at fremstille carbamoylpyridonderivater og -mellemprodukter - Google Patents

Fremgangsmåde til at fremstille carbamoylpyridonderivater og -mellemprodukter Download PDF

Info

Publication number
DK3260457T3
DK3260457T3 DK17165935.2T DK17165935T DK3260457T3 DK 3260457 T3 DK3260457 T3 DK 3260457T3 DK 17165935 T DK17165935 T DK 17165935T DK 3260457 T3 DK3260457 T3 DK 3260457T3
Authority
DK
Denmark
Prior art keywords
preparing
intermediate products
carbamoylpyridone derivatives
carbamoylpyridone
derivatives
Prior art date
Application number
DK17165935.2T
Other languages
English (en)
Inventor
Huan Wang
Steven N Goodman
Douglas Mans
Matthew Kowalski
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Application granted granted Critical
Publication of DK3260457T3 publication Critical patent/DK3260457T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17165935.2T 2010-03-23 2011-03-22 Fremgangsmåde til at fremstille carbamoylpyridonderivater og -mellemprodukter DK3260457T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31642110P 2010-03-23 2010-03-23
EP11760040.3A EP2549870B1 (en) 2010-03-23 2011-03-22 Process for preparing carbamoylpyridone derivatives and intermediates

Publications (1)

Publication Number Publication Date
DK3260457T3 true DK3260457T3 (da) 2021-02-22

Family

ID=44673569

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11760040.3T DK2549870T3 (da) 2010-03-23 2011-03-22 Fremgangsmåde til fremstilling af carbamoylpyridonderivater og -mellemprodukter
DK17165935.2T DK3260457T3 (da) 2010-03-23 2011-03-22 Fremgangsmåde til at fremstille carbamoylpyridonderivater og -mellemprodukter

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11760040.3T DK2549870T3 (da) 2010-03-23 2011-03-22 Fremgangsmåde til fremstilling af carbamoylpyridonderivater og -mellemprodukter

Country Status (20)

Country Link
US (9) US8889877B2 (da)
EP (2) EP2549870B1 (da)
JP (1) JP5490305B2 (da)
KR (1) KR101440278B1 (da)
CN (1) CN102933080B (da)
CY (2) CY1119143T1 (da)
DK (2) DK2549870T3 (da)
ES (2) ES2632346T3 (da)
HR (2) HRP20170961T1 (da)
HU (2) HUE033863T2 (da)
LT (2) LT2549870T (da)
ME (1) ME02703B (da)
PL (2) PL3260457T3 (da)
PT (2) PT2549870T (da)
RS (2) RS61436B1 (da)
SG (1) SG184186A1 (da)
SI (2) SI2549870T1 (da)
SM (2) SMT202100087T1 (da)
TW (1) TWI582097B (da)
WO (1) WO2011119566A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103951643B (zh) 2008-07-25 2015-12-09 盐野义制药株式会社 用作hiv整合酶抑制剂的化合物
KR101733625B1 (ko) 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 hiv 인테그라제 억제제 및 중간체의 합성
KR101678563B1 (ko) 2008-12-11 2016-11-22 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 hiv 인테그라제 억제제를 위한 제조방법 및 중간체
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TWI582097B (zh) 2010-03-23 2017-05-11 Viiv醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
PT2602260T (pt) 2010-08-05 2016-12-27 Shionogi & Co Processo para preparar composto possuindo atividade inibidora de integrase do vih
CA2893843C (en) 2012-12-21 2018-09-04 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9573965B2 (en) 2013-02-19 2017-02-21 Aurobindo Pharma Ltd Process for the preparation of Dolutegravir
NO2865735T3 (da) 2013-07-12 2018-07-21
DK3019503T3 (da) 2013-07-12 2017-11-20 Gilead Sciences Inc Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner
WO2015019310A1 (en) * 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015108945A2 (en) 2014-01-14 2015-07-23 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
IN2014CH00247A (da) 2014-01-21 2015-08-14 Laurus Labs Private Ltd
ZA201503540B (en) * 2014-05-20 2016-10-26 Cipla Ltd Process for preparing polycyclic carbamoyl pyridone derivatives
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (da) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
US11311545B2 (en) 2014-10-09 2022-04-26 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN104557686A (zh) * 2014-12-29 2015-04-29 徐俊烨 一种吡啶酮类化合物的合成方法
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
EP3253767A2 (en) 2015-02-06 2017-12-13 Mylan Laboratories Ltd. Processes for the preparation of dolute-gravir
TR201905009T4 (tr) 2015-04-02 2019-05-21 Gilead Sciences Inc Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
US10696636B2 (en) 2015-12-21 2020-06-30 Lupin Limited Process for the preparation of HIV integrase inhibitors
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
CN106565747A (zh) * 2016-11-10 2017-04-19 顾世海 一种制备度鲁特韦的新方法
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CA3053202C (en) * 2017-02-16 2022-10-04 Sandoz Ag Crystalline forms of cabotegravir sodium
EP3363802B1 (en) 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
US11839623B2 (en) 2018-01-12 2023-12-12 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019159199A1 (en) * 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2020012408A2 (en) 2018-07-12 2020-01-16 Laurus Labs Limited A process for purification of protected polycyclic carbamoylpyridone derivatives
CN109438334A (zh) * 2018-10-29 2019-03-08 南京杰运医药科技有限公司 一种度鲁特韦中间体的合成方法
CN109293675A (zh) * 2018-11-19 2019-02-01 遵义医学院 一种改进的度鲁特韦制备工艺
CN110128448A (zh) * 2019-05-22 2019-08-16 博诺康源(北京)药业科技有限公司 一种度鲁特韦原料及中间体中非对映异构体杂质的合成方法
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
CN111620891B (zh) * 2020-05-27 2023-07-14 上海启讯医药科技有限公司 一种多替拉韦关键中间体溶剂化物多晶型物及其制备方法和用途
CN112500336A (zh) * 2020-12-15 2021-03-16 内蒙古永太化学有限公司 一种度鲁特韦母核中间体的制备方法
CN114835730B (zh) * 2021-02-02 2026-05-01 齐鲁制药有限公司 一种制备多环氨基甲酰基吡啶酮化合物的方法
CN115572257B (zh) * 2021-06-21 2024-07-09 江西帝劢药业有限公司 一种吡啶酮类化合物的合成方法
CN116003435A (zh) * 2021-09-10 2023-04-25 河南师范大学 一种度鲁特韦的高效绿色制备方法
CN113816972B (zh) * 2021-11-17 2022-03-18 奥锐特药业(天津)有限公司 一种hiv抑制剂的制备方法及其中间体晶型
CN114605437A (zh) * 2022-04-01 2022-06-10 遵义医科大学 连续一锅法制备三个替拉韦药物的合成工艺

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524149A (en) 1982-03-15 1985-06-18 Sterling Drug Inc. 5-Alkanoyl-6-alkyl-2(1H)-pyridinones, their preparation and their cardiotonic use
US4769380A (en) 1983-04-29 1988-09-06 Merrell Dow Pharmaceuticals Inc. Cardiotonic 5-benzoyl-1,2-dihydro-2-oxo-3-pyridinecarboxylates
US4812474A (en) 1984-08-16 1989-03-14 G. D. Searle & Co. Kojic acid ether-ester derivatives
US4735964A (en) 1984-08-16 1988-04-05 G. D. Searle & Co. Kojic acid ether-ester derivatives
US4603144A (en) 1984-08-16 1986-07-29 G. D. Searle & Co. Kojic acid ether-ester derivatives
GB2280435A (en) 1993-07-29 1995-02-01 Merck & Co Inc Anti-viral agent
ES2244967T3 (es) 1995-09-29 2005-12-16 Novartis Ag Nuevas hidroxipiridinonas.
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
US6452008B2 (en) * 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
KR20040030893A (ko) * 2001-08-02 2004-04-09 뉴로크린 바이오사이언시즈 인코퍼레이티드 치환된 피리딘-4-온 및 고나도트로핀 분비 호르몬 수용체길항제로서의 이의 용도
US6426418B1 (en) 2001-11-02 2002-07-30 Apotex, Inc. Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide
CA2379370A1 (en) 2002-03-28 2003-09-28 Apotex Inc. Carboxylic acid derivatives of 3-hydroxy-4-oxo-1,4-dihydropyridine as iron chelators
US7517532B2 (en) 2002-09-11 2009-04-14 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
WO2004035577A2 (en) 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
DE10349500A1 (de) 2003-10-23 2005-06-02 Bayer Cropscience Ag Verfahren zum Herstellen von 2-Dihalogenacyl-3-amino-acrylsäureestern und 3-Dihalogenmethyl-pyrazol-4-carbonsäureestern
US7645292B2 (en) 2003-10-27 2010-01-12 Boston Scientific Scimed, Inc. Vaso-occlusive devices with in-situ stiffening elements
CA2557926A1 (en) 2004-03-09 2005-09-22 Monica Donghi Hiv integrase inhibitors
JP2007528394A (ja) 2004-03-09 2007-10-11 メルク エンド カムパニー インコーポレーテッド Hivインテグラーゼ阻害薬
ATE411030T1 (de) 2004-04-14 2008-10-15 Gilead Sciences Inc Phosphonatanaloga von hiv- integrasehemmerverbindungen
CN101014572B (zh) * 2004-09-15 2011-07-06 盐野义制药株式会社 具有hiv整合酶抑制活性的氨基甲酰基吡啶酮衍生物
CA2488034C (en) 2004-11-19 2009-10-06 Apotex Inc. Process for the manufacture of 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues
JP5068663B2 (ja) 2004-12-16 2012-11-07 ジェネラル・ケーブル・テクノロジーズ・コーポレーション フィラーエレメントを有する異質のクロストークが軽減された電気ケーブル
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
PT1874117E (pt) 2005-04-28 2013-10-17 Shionogi & Co Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse
EP1888581A2 (en) 2005-05-16 2008-02-20 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Hivインテグラーゼ阻害活性を有する多環性化合物
KR101170120B1 (ko) * 2005-07-27 2012-07-31 삼성전자주식회사 비안경식 3차원 디스플레이 장치
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
WO2007049676A1 (ja) 2005-10-27 2007-05-03 Kao Corporation 脱酸素剤、脱酸素剤中間体、脱酸素剤複合体及びその製造方法
AU2006307101A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
CN103951643B (zh) 2008-07-25 2015-12-09 盐野义制药株式会社 用作hiv整合酶抑制剂的化合物
SI2320908T1 (sl) 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
KR101678563B1 (ko) 2008-12-11 2016-11-22 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 hiv 인테그라제 억제제를 위한 제조방법 및 중간체
KR101733625B1 (ko) 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 hiv 인테그라제 억제제 및 중간체의 합성
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TWI582097B (zh) 2010-03-23 2017-05-11 Viiv醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
PT2602260T (pt) 2010-08-05 2016-12-27 Shionogi & Co Processo para preparar composto possuindo atividade inibidora de integrase do vih

Also Published As

Publication number Publication date
RS61436B1 (sr) 2021-03-31
TW201202253A (en) 2012-01-16
KR20130026433A (ko) 2013-03-13
JP5490305B2 (ja) 2014-05-14
US9938296B2 (en) 2018-04-10
US20190100533A1 (en) 2019-04-04
US20190106435A1 (en) 2019-04-11
SG184186A1 (en) 2012-10-30
DK2549870T3 (da) 2017-07-03
US20130172551A1 (en) 2013-07-04
WO2011119566A1 (en) 2011-09-29
EP2549870A1 (en) 2013-01-30
US20180186812A1 (en) 2018-07-05
EP2549870B1 (en) 2017-04-19
US10174051B2 (en) 2019-01-08
SI2549870T1 (sl) 2017-07-31
ES2632346T3 (es) 2017-09-12
PT3260457T (pt) 2021-03-03
EP3260457B1 (en) 2020-12-02
US9120817B2 (en) 2015-09-01
PL2549870T3 (pl) 2017-12-29
US8889877B2 (en) 2014-11-18
SI3260457T1 (sl) 2021-04-30
CN102933080A (zh) 2013-02-13
US10654870B2 (en) 2020-05-19
SMT201700323T1 (it) 2017-09-07
US10233196B2 (en) 2019-03-19
LT3260457T (lt) 2021-04-26
US10647728B2 (en) 2020-05-12
CN102933080B (zh) 2015-05-27
HRP20170961T1 (hr) 2017-09-22
LT2549870T (lt) 2017-07-10
JP2013522366A (ja) 2013-06-13
US20180186811A1 (en) 2018-07-05
US20150057444A1 (en) 2015-02-26
HUE052848T2 (hu) 2021-05-28
EP2549870A4 (en) 2013-10-16
ME02703B (me) 2017-10-20
CY1123958T1 (el) 2022-05-27
TWI582097B (zh) 2017-05-11
US10654871B2 (en) 2020-05-19
US9643981B2 (en) 2017-05-09
KR101440278B1 (ko) 2014-10-30
HUE033863T2 (en) 2018-01-29
PT2549870T (pt) 2017-07-05
SMT202100087T1 (it) 2021-03-15
US20190100532A1 (en) 2019-04-04
US20150329559A1 (en) 2015-11-19
HRP20210255T1 (hr) 2021-04-02
EP3260457A1 (en) 2017-12-27
PL3260457T3 (pl) 2021-06-28
RS56072B1 (sr) 2017-10-31
CY1119143T1 (el) 2018-02-14
ES2856020T3 (es) 2021-09-27
US20170204117A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
HRP20170961T1 (hr) Postupak dobivanja karbamoilpiridonskih derivata i međuprodukata
FI20115156A7 (fi) Maitopohjainen tuote ja menetelmä sen valmistamiseksi
DK2602089T3 (da) Resinform til nanotryk og fremgangsmåde til fremstilling deraf
DK2683731T3 (da) C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf
BR112013030472A2 (pt) formulação farmacêutica, artigo de fabricação e método
BR112013021373A2 (pt) aparelho e método de bebida preparada
IL235734B (en) Process for the preparation of treprostinil and derivatives thereof
PL2601105T3 (pl) Sposób i system przygotowania fiolki
PL2678035T3 (pl) Pochodne fenalen-1-onu, sposób ich wytwarzania i zastosowanie
DK2555629T3 (da) Proteinprodukt og fremgangsmåde til fremstilling af injicérbart proteinprodukt
DK2622532T3 (da) Fremgangsmåde til kollaborativ beregning
PL3299356T3 (pl) Sposób wytwarzania pleuromutylin
AP3222A (en) Germination-stimulant carbamate derivatives and process for preparation thereof
PL2627656T3 (pl) Sposób wytwarzania dihydropterydynonów i ich produktów pośrednich
FI20095500L (fi) Tuote ja menetelmä sen valmistamiseksi
FI20090142A0 (fi) Uudet menetelmät ja tuotteet
ZA201503454B (en) Method of plant growth promotion using carboxamide derivatives
IL231505B (en) Pharmaceutical preparation and method for its production
IL229968A0 (en) Tetrazolyloxy derivatives and methods for their production
FI20115851L (fi) Tuote ja menetelmä sen valmistamiseksi
CU24148B1 (es) Intermedios de agomelatina y método de preparación de éstos
PL2694532T3 (pl) Pochodne aureobasidin i sposoby syntezy
IL231798A0 (en) Method and composition
SG11201401454XA (en) Derivative of butylphthalide and preparation method and use thereof
FI20105928A0 (fi) Termografiamenetelmä ja -järjestelmä